Less invasive staging for endometrial cancer put to the test

NCT ID NCT02598219

Ongoing Knowledge-focused Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial compares a less invasive sentinel node biopsy approach to standard staging methods in 262 women with early-stage endometrial cancer at intermediate or high risk of recurrence. The goal is to see if the sentinel node policy reduces surgical complications while still accurately detecting cancer spread. Participants receive a radioactive tracer injection into the cervix before surgery to map the first lymph nodes the cancer might reach.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pre-operative sentinel node mapping with radionucleide (Nanocis, Nanocoll, or Rotop-nanoHSA)
What this could lead to: If successful, this could show that sentinel node biopsy is safer and equally effective as standard staging for certain endometrial cancers, potentially becoming the new standard of care.
What could go wrong: This is a phase 3 trial, but results are not yet available. The approach may not detect all cancer spread, and individual outcomes may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Endometrioid endometrial carcinoma endometrioid adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIOID CARCINOMA NON ENDOMETRIOID CARCINOMA

Contacts and locations

Locations

Centre Georges François Leclerc

Dijon, France
Centre Hospitalier Régional Universitaire

Besançon, 25000, France
Centre Jean Perrin

Clermont-Ferrand, 63011, France
Centre Léon Bérard

Lyon, 69008, France
Centre Oscar Lambret

Lille, 59020, France
Centre Paul Strauss

Strasbourg, 67065, France
Hôpital Européen Georges Pompidou

Paris, 75015, France
Hôpital Jeanne de Flandres, CHRU Lille

Lille, 59037, France
Hôpital La Pitié-Salpêtrière

Paris, 75013, France
Hôpital Mère-Enfant, CHU Limoges

Limoges, 87042, France
ICM Val d'Aurelle

Montpellier, 34298, France
Institut Bergonié

Bordeaux, 33076, France
Institut Claudius Regaud

Toulouse, 31059, France
Institut Paoli Calmettes

Marseille, 13273, France
Institut de Cancérologie de l'Ouest, René Gauducheau

Saint-Herblain, 44805, France
Polyclinique Urbain V

Avignon, 84036, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.